Getting specific: monoclonal antibodies in multiple sclerosis.
about
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewCaerulomycin A suppresses immunity by inhibiting T cell activityA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesLong-term daclizumab therapy in relapsing-remitting multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Safety of monoclonal antibodies for the treatment of multiple sclerosis.Engaging neuroscience to advance translational research in brain barrier biology.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Catalpol induces oligodendrocyte precursor cell-mediated remyelination in vitro.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisSuccessful management of a neurology infusion practice.Update on the treatment options for multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.Alternative affinity tools: more attractive than antibodies?Monoclonal antibodies in neuroinflammatory diseases.Drugs in development for relapsing multiple sclerosis.Multiple sclerosis treatment and infectious issues: update 2013.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?Monoclonal antibodies as diagnostics; an appraisal[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].A monoclonal antibody selection for immunohistochemical examination of lymphoid tissues from non-human primates.Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.United Europeans for development of pharmacogenomics in multiple sclerosis network.Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
P2860
Q26781389-69FB9245-B2D1-4267-B48D-E3CB07384871Q26999417-0522505F-423F-47CE-AD66-B6477C529411Q27348735-3772CA2C-01D0-44DA-9F2A-B2E1BC61690FQ28068709-7057641A-018A-455D-979B-CF8AB21D24A6Q34409257-628EC56B-E41B-4D70-90B6-EC7BDE5AEC71Q34468304-C716AD28-6EB8-4FF5-90D4-0E24B5064792Q34542922-E9558CC2-9CC8-40C1-8EEE-A6095561605AQ35909313-E9EC1BCB-D304-4843-BF58-230EA7DAB279Q36396476-75F8133C-1C6C-4910-B205-E55E8D9B9693Q36420302-85D9BAB9-E424-48FA-B3D4-9CD4D1E7F96CQ36484443-FBB4F3A7-0693-40A7-A94A-19C690AA9E5DQ37442077-32A46E89-22BD-43A5-A5D6-48DD8869B988Q37729045-9932CD78-B359-4E45-B984-F67130EA289DQ37814815-D18CDA3C-CD45-4E4F-8225-F6C167690882Q37869534-04DAB9D0-66B3-4775-AD83-7273B9BB0B50Q38092121-EB67A3E9-9325-4597-98E0-4CB7CFB02E4EQ38101004-3058EB42-7C7E-47E4-B261-F19A175F9320Q38153471-2A791CC8-E5EA-4FC8-B480-EACFB15833D9Q38364547-D7FCFDF6-ABE0-4036-8928-59BB61EE39AAQ39391443-EB24407F-171D-45E4-8FB0-D0718296B1B5Q39400059-380DE4E1-58DF-43A2-8734-B45716DD4E7CQ40965269-46C8E5D0-AD20-4CA0-8319-7E48A53908F8Q41102105-546564D1-4512-4F20-AF5E-267820DFF35DQ41991893-980931AA-23DF-4EF5-9C6D-5498F1A65F8FQ42171615-29A94067-3833-4881-B934-29DED367FD56Q43838731-EFE878EE-9E11-4069-883A-CEC39BB6BCB6Q48523985-69BC61A7-D24A-437E-B2FB-D40ED693D553Q48881943-33E574B9-E384-4614-9BB8-5001103CEF80
P2860
Getting specific: monoclonal antibodies in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Getting specific: monoclonal antibodies in multiple sclerosis.
@en
Getting specific: monoclonal antibodies in multiple sclerosis.
@nl
type
label
Getting specific: monoclonal antibodies in multiple sclerosis.
@en
Getting specific: monoclonal antibodies in multiple sclerosis.
@nl
prefLabel
Getting specific: monoclonal antibodies in multiple sclerosis.
@en
Getting specific: monoclonal antibodies in multiple sclerosis.
@nl
P1433
P1476
Getting specific: monoclonal antibodies in multiple sclerosis
@en
P2093
Andreas Lutterotti
P304
P356
10.1016/S1474-4422(08)70110-8
P50
P577
2008-06-01T00:00:00Z